First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato De Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Jänne PA, Heymach JV, Zhang J, Ricciuti B, Le X

Open source

DOI: 10.1158/1078-0432.ccr-25-1735
Published: 2025 Nov 14
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-1735,
  title = {First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.},
  author = {Pecci F and Li H and Di Federico A and Wu J and Chen H and Gariazzo E and Mantuano F and Garbo E and Aldea M and Santo V and Gibbons D and Tran H and Paoloni F and Rossato De Almeida G and Metro G and De Giglio A and Gelsomino F and Wang X and Tiseo M and Rotow J and Ardizzoni A and Lee JJ and Awad MM and Addeo A and Hong L and Negrao MV and Jänne PA and Heymach JV and Zhang J and Ricciuti B and Le X},
  year = {2025},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-1735},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-1735}
}

RIS

TY  - JOUR
TI  - First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
AU  - Pecci F
AU  - Li H
AU  - Di Federico A
AU  - Wu J
AU  - Chen H
AU  - Gariazzo E
AU  - Mantuano F
AU  - Garbo E
AU  - Aldea M
AU  - Santo V
AU  - Gibbons D
AU  - Tran H
AU  - Paoloni F
AU  - Rossato De Almeida G
AU  - Metro G
AU  - De Giglio A
AU  - Gelsomino F
AU  - Wang X
AU  - Tiseo M
AU  - Rotow J
AU  - Ardizzoni A
AU  - Lee JJ
AU  - Awad MM
AU  - Addeo A
AU  - Hong L
AU  - Negrao MV
AU  - Jänne PA
AU  - Heymach JV
AU  - Zhang J
AU  - Ricciuti B
AU  - Le X
PY  - 2025
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-1735
UR  - https://doi.org/10.1158/1078-0432.ccr-25-1735
ER  -

APA

F, P., H, L., A, D. F., J, W., H, C., E, G., F, M., E, G., M, A., V, S., D, G., H, T., F, P., G, R. D. A., G, M., A, D. G., F, G., X, W., M, T., J, R., A, A., JJ, L., MM, A., A, A., L, H., MV, N., PA, J., JV, H., J, Z., B, R., & X, L. (2025). First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-1735

Source records

pubmed · retrieved 2026-09-27T12:00:26.581Z